Recombinant erythropoietin - Prolong Pharmaceuticals/Zydus Cadila

Drug Profile

Recombinant erythropoietin - Prolong Pharmaceuticals/Zydus Cadila

Alternative Names: PEG-EPO; PEGEPO - Cadila/Prolong; Pegylated erythropoietin - Cadila/Prolong; ZY-7318

Latest Information Update: 09 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prolong Pharmaceuticals; Zydus Cadila
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaemia

Most Recent Events

  • 09 Nov 2016 Prolong Pharmaceuticals plans a phase Ib trial for Beta thalassemia in Thailand (NCT02950857)
  • 09 Oct 2015 Recombinant erythropoietin is still in phase I trials for Anaemia in India (Zydus pipeline, October 2015)
  • 30 Sep 2013 Phase-I clinical trials in Anaemia (associated with chronic renal failure) in India (Parenteral) before Sep 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top